Wuhan Mingde Bio-Technology Co., Ltd.
Announcement on the Completion of Transfer of Underlying Assets for Major Asset Purchase
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.
I. Overview of the Transaction
Wuhan Mingde Bio-Technology Co., Ltd. (hereinafter referred to as the "Company") acquired 100% equity in Wuhan Bekaier Rescue Products Co., Ltd. (hereinafter referred to as "Bekaier") held by Blue Sail Medical Co., Ltd. (hereinafter referred to as "Blue Sail Medical") through cash payment (hereinafter referred to as the "Transaction"). The Fifth Board of Directors' Seventh Meeting, the Fifth Board of Directors' Ninth Meeting, and the First Extraordinary Shareholders' Meeting in 2026 deliberated and approved the proposals related to this transaction. This transaction constitutes a major asset restructuring, but not a related-party transaction or a backdoor listing. The transaction is a cash transaction, does not involve the issuance of shares or the raising of supporting funds, and will not lead to a change in the listed company's control.
As of the date of this announcement, the transfer of the underlying assets involved in this transaction has been completed.
II. Implementation of the Transaction
(I) Transfer of Underlying Assets
According to the transaction plan, the underlying assets of this transaction are the 100% equity of Bekaier held by Blue Sail Medical. On August 14, 2026, the industrial and commercial change registration for the Company's purchase of 100% equity in Bekaier held by Blue Sail Medical was completed, and Bekaier obtained a new "Business License" reissued by the Wuhan Qiaokou District Administrative Approval Bureau.
As of the date of this announcement, the 100% equity of Bekaier held by Blue Sail Medical has been fully transferred and registered in the Company's name.
(II) Payment of Transaction Consideration